预约演示

Nabla Bio secures $26m in Series A funding round

2024-05-15

蛋白降解靶向嵌合体

Nabla Bio secures $26m in Series A funding round

Preview

来源: Pharmaceutical Technology

Nabla Bio co-founders Surge Biswas and Frances Anastassacos at the company’s labs in Cambridge, Massachusetts in the US. Credit: Business Wire / Nabla Bio.

US pharmaceutical company Nabla Bio has secured $26m for generative protein design in a Series A financing round led by Radical Ventures.

The round included full participation from all existing investors.

Nabla has also entered strategic partnerships with Bristol Myers Squibb, AstraZeneca and Takeda.

These partnerships could exceed $550m in upfront and milestone payments, in addition to royalty payments.

Nabla Bio specialises in the integration of AI and wet-lab technologies for atomically precise drug design and the high-throughput evaluation of drug function.

See Also:CinDome Pharma secures $40m to advance gastroparesis treatment

Preview

来源: Pharmaceutical Technology

DM-5167 by Dime Bio for Solid Tumor: Likelihood of Approval

Preview

来源: Pharmaceutical Technology

The company’s initial focus is on antibodies that target multipass membrane proteins such as G protein-coupled receptors, ion channels and transporters.

These proteins are challenging to treat because of their membrane-integrated nature, reduced extracellular availability and structural similarity across targets.

Multipass membrane proteins, which constitute two-thirds of all cell surface proteins, play a central role in controlling cell behaviour. They have long been considered the “holy grail” of protein drug development.

Nabla’s generative protein design platform is now making hundreds of these previously inaccessible targets available by enabling the accurate designing of conformation and target-selective antibody binders.

To enhance the patient impact of its platform, Nabla is collaborating with other pharmaceutical companies known for successful drug development.

These partnerships aim to enhance their pipelines with high-quality drug candidates targeting some of the most challenging and high-impact proteins.

They are also aimed at generating insights into disease biology and platform development.

Since its launch in December 2021 with support from Khosla Ventures and Zetta Venture Partners, Nabla Bio has secured $37m in funding.

Nabla co-founder and CEO Surge Biswas stated: “We are unlocking new opportunities to build highly selective drugs against validated, but hard-to-drug targets with a degree of structural precision not previously possible.

“We are excited to welcome Radical Ventures as our newest investor and to announce collaborations with three of the world’s largest pharmaceutical companies to help us bring our work closer to patients.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构